LILLY RAISES REVENUE GUIDE, TRIMS EPS OUTLOOK

Eli Lilly ($LLY) posted third-quarter revenue of $24.4 billion, well above the $22.52 billion Wall Street expected, driven by Mounjaro and Zepbound demand. The company raised its full-year revenue guidance to $91 billion-$92 billion, up sharply from the $85 billion-$87 billion range it gave in August. Yet full-year adjusted EPS guidance actually slipped to $35-$36, down from $35.50-$36.50, as acquired R&D charges ate into the bottom line.